\begin{tabular}{lccccccccc}
   \hline
 
         \multicolumn{1}{l}{COVE} & \multicolumn{1}{c}{Tertile}   & \multicolumn{1}{c}{No. cases /}   & \multicolumn{1}{c}{Attack}   & \multicolumn{2}{c}{Haz. Ratio}                     & \multicolumn{1}{c}{P-value}   & \multicolumn{1}{c}{Overall P-}      & \multicolumn{1}{c}{Overall q-}   & \multicolumn{1}{c}{Overall} \\ 
         \multicolumn{1}{l}{Immunologic Marker}            & \multicolumn{1}{c}{}          & \multicolumn{1}{c}{No. at-risk**} & \multicolumn{1}{c}{rate}   & \multicolumn{1}{c}{Pt. Est.} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{(2-sided)} & \multicolumn{1}{c}{value***} & \multicolumn{1}{c}{value $\dagger$} & \multicolumn{1}{c}{FWER} \\ 
         \hline
 
    Anti Spike IgG (IU/ml) & Lower & 20/3,702 & 0.0054 & 1 & N/A & N/A & 0.004 & N/A & N/A \\ 
   & Middle & 19/3,705 & 0.0051 & 0.57 & (0.28-1.16) & 0.122 &     &  &  \\ 
   & Upper & 20/3,750 & 0.0053 & 0.26 & (0.11-0.57) & 0.001 &     &  &  \\ 
  Anti RBD IgG (IU/ml) & Lower & 26/3,722 & 0.0070 & 1 & N/A & N/A & 0.001 & N/A & N/A \\ 
   & Middle & 13/3,740 & 0.0035 & 0.33 & (0.16-0.67) & 0.002 &     &  &  \\ 
   & Upper & 20/3,695 & 0.0054 & 0.29 & (0.14-0.61) & 0.001 &     &  &  \\ 
  Pseudovirus-nAb ID50 & Lower & 20/3,690 & 0.0054 & 1 & N/A & N/A & 0.052 & N/A & N/A \\ 
   & Middle & 23/3,749 & 0.0061 & 0.97 & (0.50-1.89) & 0.932 &     &  &  \\ 
   & Upper & 16/3,718 & 0.0043 & 0.45 & (0.21-0.95) & 0.037 &     &  &  \\ 
  Pseudovirus-nAb ID80 & Lower & 20/3,754 & 0.0053 & 1 & N/A & N/A & 0.028 & N/A & N/A \\ 
   & Middle & 26/3,719 & 0.0070 & 1.14 & (0.61-2.16) & 0.678 &     &  &  \\ 
   & Upper & 13/3,685 & 0.0035 & 0.45 & (0.21-0.96) & 0.038 &     &  &  \\ 
    
 \multicolumn{8}{l}{} \\ 

 \multicolumn{2}{l}{Placebo} & 1169/11,426&0.1023&\multicolumn{4}{l}{}  \\ 
 \hline
\end{tabular}
